Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423473 | 1.00 | GSR (0.47) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL29397210 | 0.92 | GSR (0.50) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL1923416 | 0.91 | GSR (0.56) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL28264447 | 0.91 | GSR (0.56) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL30445302 | 0.91 | NMT1 (0.47) | GSRNMT2NMT1FOLH1CPB2 | |
| SCHEMBL29618013 | 0.90 | NMT2 (0.42) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL31593295 | 0.89 | NMT1 (0.45) | DPP8DPP9DPP7NMT2NMT1 | |
| SCHEMBL29727679 | 0.89 | FOLH1 (0.50) | DPP8DPP9NMT2NMT1FOLH1 | |
| SCHEMBL31188429 | 0.89 | GSR (0.47) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL30080483 | 0.89 | FOLH1 (0.48) | GSRDPP8DPP9DPP7GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | claimed |
| US-20230295276-A1 | ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF | NOVASCOPE BIOCHIPS INC. (US) | 2023-09-21 | — | — | US | claimed |
| WO-2023178265-A2 | ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF | NOVASCOPE BIOCHIPS INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023094980-A1 | ANTIBODIES TO CORONAVIRUS | FONDAZIONE TOSCANA LIFE SCIENCES (IT) | 2023-06-01 | — | — | WO | claimed |
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2025-05-22 | — | — | US | disclosed |
| US-20250115661-A1 | BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR | THE ROCKEFELLER UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-20230295276-A1 | ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF | NOVASCOPE BIOCHIPS INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178265-A2 | ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF | NOVASCOPE BIOCHIPS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023094980-A1 | ANTIBODIES TO CORONAVIRUS | FONDAZIONE TOSCANA LIFE SCIENCES (IT) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | GSR 781/4885DPP8 1743/4885DPP9 1565/4885 |
| US-12128110-B2 | Transglutaminase conjugation method and linker | TGM3, TGM2, TGM1 | GSR 716/4885DPP8 2007/4885DPP9 1834/4885 |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | GSR 710/4885DPP8 1915/4885DPP9 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.